Microba Life Sciences (ASX:MAP) Cash-to-Debt : 20.34 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Microba Life Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 20.34.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Microba Life Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Microba Life Sciences's Cash-to-Debt or its related term are showing as below:

ASX:MAP' s Cash-to-Debt Range Over the Past 10 Years
Min: 20.34 Med: 28.21 Max: 35.35
Current: 20.34

During the past 2 years, Microba Life Sciences's highest Cash to Debt Ratio was 35.35. The lowest was 20.34. And the median was 28.21.

ASX:MAP's Cash-to-Debt is ranked better than
86.26% of 211 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.32 vs ASX:MAP: 20.34

Microba Life Sciences Cash-to-Debt Historical Data

The historical data trend for Microba Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Microba Life Sciences Cash-to-Debt Chart

Microba Life Sciences Annual Data

Trend

Jun22

Jun23

Cash-to-Debt

23.08

28.21

Microba Life Sciences Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	34.91	23.08	35.35	28.21	20.34

Competitive Comparison of Microba Life Sciences's Cash-to-Debt

For the Diagnostics & Research subindustry, Microba Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microba Life Sciences's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Microba Life Sciences's Cash-to-Debt falls into.

Microba Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Microba Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	32.044	/	(0.902	+	0.234)
	=	28.21

Microba Life Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	28.051	/	(0.868	+	0.511)
	=	20.34

Microba Life Sciences (ASX:MAP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Microba Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Microba Life Sciences (ASX:MAP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000

Website

https://www.microba.com

Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome which includes delivering gut microbiome testing services globally to consumers, clinicians, and researchers. The company's segment includes Testing Services, and Research and Development.

Microba Life Sciences (ASX:MAP) Headlines

No Headlines